ABIONYX Pharma Balance Sheet Health
Financial Health criteria checks 4/6
ABIONYX Pharma has a total shareholder equity of €8.6M and total debt of €2.0M, which brings its debt-to-equity ratio to 23.6%. Its total assets and total liabilities are €18.2M and €9.5M respectively.
Key information
23.6%
Debt to equity ratio
€2.04m
Debt
| Interest coverage ratio | n/a |
| Cash | €4.03m |
| Equity | €8.64m |
| Total liabilities | €9.53m |
| Total assets | €18.18m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ABNXP's short term assets (€9.6M) exceed its short term liabilities (€5.7M).
Long Term Liabilities: ABNXP's short term assets (€9.6M) exceed its long term liabilities (€3.8M).
Debt to Equity History and Analysis
Debt Level: ABNXP has more cash than its total debt.
Reducing Debt: ABNXP's debt to equity ratio has reduced from 42.8% to 23.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ABNXP has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ABNXP has less than a year of cash runway if free cash flow continues to grow at historical rates of 29.8% each year.